Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone and Vitamin E in NAFLD
NCT01147523Phase 2Completed
- Sponsor
- Aristotle University of Thessaloniki
- Start
- Jan 2010
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of spironolactone in non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by Aristotle University of Thessaloniki. Primary endpoint: Serum adipocytokines levels at 52 weeks. Started Jan 2010; status: completed.
02
Drugs
spironolactone
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT01147523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01147523.